The SilkMatrix™ Platform — Silk Biomaterials Science

Why Silk Fibroin

A biomaterial nature already perfected.

Silk has been used safely in surgery for over a century as suture material. Modern processing now lets us isolate and re-engineer its two key proteins — fibroin and sericin — into advanced, controllable biomaterials with properties no synthetic polymer can replicate.

✓FibroinThe structural protein. β-sheet crystallinity gives it compressive strength comparable to bone — without metal, without foreign chemicals.
✓SericinThe bioactive, hydrophilic protein. Supports cell adhesion and proliferation — ideal for wound care and cell-interactive matrices.
✓Blends & compositesFibroin and sericin combined in tunable ratios, optimised per clinical indication.
✓Indigenous raw materialIndia is one of the world’s largest silk producers. Supply chain risk is low, and the material is fully renewable.

Silk cocoons and raw silk fibre beside a labelled vial of clear silk-fibroin solution in a laboratory

Raw Bombyx mori cocoons → the starting material for every SilkMatrix device.

From Cocoon to Implant

How the platform works.

A controlled, reproducible four-stage process converts raw silk into medical-grade biomaterial with defined mechanical and degradation properties. No synthetic polymers. No metal. No petrochemicals.

Raw Cocoon

Bombyx mori silk cocoons — domestically sourced, naturally renewable.

Starting material

Extract & Purify

Degumming removes sericin. Dissolution in LiBr yields pure fibroin solution. Dialysis removes salts.

Fibroin isolation

Formulate & Form

Solution is cast, freeze-dried, or electrospun into films, porous scaffolds, or solid load-bearing geometries.

Device forming

Stabilise & Tune

Methanol vapour or heat treatment induces β-sheet crystallinity — locking in target strength and resorption timeline.

β-sheet crystallisation

Raw silk cocoon → purified fibroin solution → formed & stabilised bioresorbable device. Device-grade manufacturing protocols will be established during the Scale-up Gate.

Renewable sourcing

Indian sericulture produces ~35,000 MT of raw silk annually. No import dependency for the core feedstock.

Precision dissolution

LiBr dialysis yields reproducible fibroin at defined concentration and molecular-weight distribution — critical for downstream consistency.

Multiple form factors

The same protein stock can be formed into screws, films, porous scaffolds, meshes, or hydrogels — without changing the core chemistry.

Tunable resorption

β-sheet content sets degradation rate: higher crystallinity → slower resorption. Matched to the tissue-healing window of each device.

The Mechanism

Why fibroin is mechanically strong: β-sheet crystallinity.

The molecular architecture behind every SilkMatrix device — and the dial that makes one protein serve radically different clinical needs.

Self-assembling structure

Random-coil fibroin chains fold into tightly packed β-sheet domains during processing — the same architecture responsible for spider-silk toughness.

Precisely controllable

The proportion of β-sheet crystallinity is set by temperature, solvent concentration, and methanol vapour exposure — a reproducible, single-step tuning process.

Wide mechanical range

From 0% (soft hydrogel) to ~55% crystallinity (load-bearing, bone-comparable strength) — one protein platform, the full clinical range.

β-sheet crystallinity Conformational control Tunable degradation All-protein matrix No synthetic additives ~55% max crystallinity

Scanning electron micrograph view of a silk-fibroin scaffold showing a honeycomb of interconnected pores approximately 100–300 µm in diameter

Interconnected pore architecture of a silk-fibroin scaffold — designed to support cell ingrowth and nutrient transport.

Engineered Properties

Tunable across the properties that matter.

Because the platform controls the material at the protein level — not through fillers or coatings — a single science can serve very different clinical needs.

✓Mechanical strengthβ-sheet content dialled from soft hydrogel to forms with compressive strength comparable to cortical bone.
✓Resorption rateWeeks to years — matched to healing windows from wound closure through bone union.
✓Porosity & architecture100–300 µm interconnected pores, sized for cell ingrowth and vascularisation.
✓Surface bioactivityProtein surface promotes cell adhesion without synthetic adhesion factors — the scaffold itself is bioactive.
✓Degradation by-productsNatural amino acids — not the acidic monomers of PLA/PGA devices that can cause local pH drop.

Bone-like

Compressive strength comparable to human cortical bone in the founder’s feasibility research

100–300 µm

Interconnected pore diameter — optimal range for cell ingrowth and vascularisation

ISO 10993

Biological-evaluation framework guiding the biocompatibility programme

100 yrs

Silk’s clinical safety record as surgical suture — the longest of any implantable biomaterial

Strength comparisons and pore-size data reflect the founder’s documented academic feasibility research. Device-specific performance will be established through the company’s own mechanical testing, ISO 10993 biological evaluation, and preclinical studies before any regulatory submission.

The Control Levers

Three variables. Infinite combinations.

Every SilkMatrix device is programmed during processing by adjusting these three parameters — no reformulation needed between product lines.

Protein concentration

Higher fibroin concentration increases matrix density and initial stiffness. Controls both forming behaviour and degradation profile.

Typical range: 4–20 % w/v

Forming method

Casting → dense films. Freeze-drying → open porous scaffolds. Electrospinning → nanofibrous meshes. Same protein stock, different architecture.

Cast · Lyophilise · Electrospin · Mould

β-sheet induction

Methanol vapour, water-annealing, or heat treatment induces β-sheet crystallinity — setting mechanical strength and resorption rate in a single step.

0 % → ~55 % crystallinity

Competitive Advantage

Why silk over conventional biomaterials.

Every dimension where silk fibroin outperforms or meaningfully differentiates from the two incumbent categories.

Dimension	Permanent metal (Ti / SS)	Synthetic resorbables (PLA / PGA)	SilkMatrix™ silk fibroin
Removal surgery required	Often required	Not required	Not required
Stress shielding	Common (high stiffness mismatch)	Reduced	Reduced — stiffness tunable to match tissue
Degradation by-products	None (permanent implant)	Lactic/glycolic acid — local pH drop	Natural amino acids — physiologically benign
Biological activity	Inert	Mostly inert	Bioactive protein surface — supports cell adhesion
Imaging artefact (MRI/CT)	Significant metal artefact	Minimal	None — fully protein, radiolucent
Porosity for tissue ingrowth	Not possible (solid metal)	Limited by processing	Engineered interconnected porosity
Raw-material origin	Imported alloys	Petrochemical synthesis	Indigenous silk — renewable, domestic supply

Comparative statements describe the design intent and established literature properties of silk biomaterials versus incumbent device categories. Device-specific performance will be established through the company’s own testing, ISO 10993 biological evaluation, and preclinical studies before any regulatory submission.

The SilkMatrix™ biomaterials platform.